Next Article in Journal
Potency of Hexaconazole to Disrupt Endocrine Function with Sex Hormone-Binding Globulin
Next Article in Special Issue
Pro-Arrhythmic Potential of Accumulated Uremic Toxins Is Mediated via Vulnerability of Action Potential Repolarization
Previous Article in Journal
Role of SOCS and VHL Proteins in Neuronal Differentiation and Development
Previous Article in Special Issue
SCN5A Variants as Genetic Arrhythmias Triggers for Familial Bileaflet Mitral Valve Prolapse
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers

1
International Laser Center CVTI, 841 04 Bratislava, Slovakia
2
Premedix Academy, 811 02 Bratislava, Slovakia
3
National Institute for Cardiovascular Diseases, 833 08 Bratislava, Slovakia
4
Faculty of Medicine, Comenius University in Bratislava, 831 01 Bratislava, Slovakia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(4), 3881; https://doi.org/10.3390/ijms24043881
Submission received: 27 December 2022 / Revised: 8 February 2023 / Accepted: 14 February 2023 / Published: 15 February 2023

Abstract

Left ventricular hypertrophy (LVH) refers to a complex rebuilding of the left ventricle that can gradually lead to serious complications—heart failure and life-threatening ventricular arrhythmias. LVH is defined as an increase in the size of the left ventricle (i.e., anatomically), therefore the basic diagnosis detecting the increase in the LV size is the domain of imaging methods such as echocardiography and cardiac magnetic resonance. However, to evaluate the functional status indicating the gradual deterioration of the left ventricular myocardium, additional methods are available approaching the complex process of hypertrophic remodeling. The novel molecular and genetic biomarkers provide insights on the underlying processes, representing a potential basis for targeted therapy. This review summarizes the spectrum of the main biomarkers employed in the LVH valuation.
Keywords: left ventricular hypertrophy; ventricular tachyarrhythmias; biomarkers left ventricular hypertrophy; ventricular tachyarrhythmias; biomarkers

Share and Cite

MDPI and ACS Style

Bacharova, L.; Kollarova, M.; Bezak, B.; Bohm, A. Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers. Int. J. Mol. Sci. 2023, 24, 3881. https://doi.org/10.3390/ijms24043881

AMA Style

Bacharova L, Kollarova M, Bezak B, Bohm A. Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers. International Journal of Molecular Sciences. 2023; 24(4):3881. https://doi.org/10.3390/ijms24043881

Chicago/Turabian Style

Bacharova, Ljuba, Marta Kollarova, Branislav Bezak, and Allan Bohm. 2023. "Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers" International Journal of Molecular Sciences 24, no. 4: 3881. https://doi.org/10.3390/ijms24043881

APA Style

Bacharova, L., Kollarova, M., Bezak, B., & Bohm, A. (2023). Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers. International Journal of Molecular Sciences, 24(4), 3881. https://doi.org/10.3390/ijms24043881

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop